Nephrotic syndrome is a rare complication of allo-SCTSCT and is often associated with chronic GVHD. Its incidence may increase with the increase in age of transplant recipients, donor lymphocyte infusion and the increase in use of blood stem cell grafts. [1] [2] [3] In a report published in 2006, nine patients with chronic GVHD-associated nephrotic syndrome were studied. 4 Two out of these nine patients received rituximab therapy with an excellent response. We now report on repeated courses of rituximab in patients with nephrotic syndrome associated with chronic GVHD.
Patient 1 was a 36-year-old allogeneic SCT recipient for severe aplastic anemia. He was conditioned with CY and equine antithymocyte globulin and received G-CSFmobilized PBSCs from his HLA-identical brother. Posttransplant immunosuppression comprised cyclosporine, and the plan was to taper the drug after 1 year. A few weeks after the initiation of the taper, he presented with rash, mouth sores, liver dysfunction and diarrhea; the clinical picture resembled 'overlap syndrome'. 5 He was started on methylprednisolone 1 mg/kg/day. Therapy was tolerated poorly, owing to steroid-induced diabetes. He developed renal insufficiency despite the adjustment in cyclosporine dose with 176.8-221.0 mmol/L creatinine, and methylprednisolone was tapered off completely. Approximately 34 months after transplantation, he developed anasarca and hypertension with an elevated creatinine level of 212.2 mmol/L and a proteinuria level of 15 g every 24 h, which was associated with hypoalbuminemia. Renal biopsy showed features consistent with membranous glomerulonephritis on immunofluorescence (a bright granular peripheral capillary loop staining in a membranous pattern with IgG, C3, C1q, kappa and lambda) and EM (innumerable electron-dense immune-type deposits along the subepithelial surface of the glomerular basement membrane). Serum complements were within normal range and negative for cryoglobulin, ANA, ANCA, and antibodies against hepatitis B, hepatitis C and HIV. Following the biopsy, he was started on methylprednisolone. Despite steroid therapy, his anasarca progressed unabated and his urinary protein level rose to nearly 40 g every 24 h. The decision to give rituximab was made on account of worsening serum creatinine level (up to 424.3 mmol/L); he was listed to receive renal transplantation. The first course of a fourweekly dose of rituximab 375 mg/M 2 was initiated. The patient had a dramatic response with diminished proteinuria levels. Over the subsequent years, he had three more exacerbations of proteinuria, each time with a proteinuria level of 415 g every 24 h, and treatments with repeated courses of rituximab were successful in controlling his proteinuria. The last course of rituximab was given in an attempt to prevent further resurgence of proteinuria. He was able to tolerate all the therapy without difficulty. Currently he is at 99 months post transplant without clinical signs of chronic GVHD. The clinical course of proteinuria and concurrent immunosuppressive therapy are depicted in Figure 1 .
Patient 2 was a 48-year-old allogeneic SCT recipient for IgG lambda myeloma. His renal function was normal at diagnosis. After four cycles of VAD (vincristine, adriamycin and dexamethasone) chemotherapy, he underwent allo-SCT from his HLA-matched sister after conditioning with BU, CY and modified TBI. The post-transplant clinical course was complicated by acute GVHD involving the skin and gastrointestinal tract with progression to chronic GVHD with extensive sclerodermoid involvement and marked restriction of his chest wall. Tacrolimus and mycophenolate mofetil given for GVHD prophylaxis were maintained without interruption throughout the posttransplant course and intermittent courses of methylprednisolone were given during clinical exacerbation of his GVHD. Approximately a year after transplant, he developed nephrotic-range proteinuria and a biopsy-confirmed membranous glomerulonephritis. Sirolimus was added with some response, but he had gastrointestinal intolerance to oral medications. Rituximab was administered at 14 months post transplant as described in our previous report. 6 At 94 months after transplant, he developed increasing peripheral edema associated with heavy proteinuria and anasarca with a peak proteinuria level of 90 g www.nature.com/bmt every 24 h. He was bed-ridden with massive ascites, and oozing of interstitial fluid over areas of skin ulcers, peripheral and scrotal edema. The second and third courses of rituximab were administered at 95 and 98 months after transplantation (see Figure 2 : the first course given at 14 months is not shown and was previously reported 6 ). He had a dramatic response to therapy with marked decrease in proteinuria level, although still in the nephrotic range. He is currently at 108 months post transplant and is ambulatory with stable extensive sclerodermoid GVHD.
We have previously described the efficacy of rituximab in the treatment of chronic GVHD, 6 which was later confirmed by other investigators. 7, 8 There are increasing reports of nephrotic syndrome-associated chronic GVHD in the recent years. Most of these cases were associated with chronic GVHD and some of these patients were successfully treated with rituximab. 6 We reported on two patients who developed nephrotic syndrome associated with chronic GVHD who were treated with repeated courses of rituximab. One of our patients in the initial report was later treated with two additional cycles (case 2). Both patients tolerated repeated cycles of therapy with a reduction in urinary protein excretion accompanied by improvement in other-organ involvement by chronic GVHD. Recurrence of proteinuria and response to retreatment suggest a possibility of maintenance treatment with rituximab, as many of the soft-tissue and skin manifestations can be subtle and slowly progressive that they may eventually cause permanent organ damage. Skin and soft-tissue involvement by chronic GVHD in case 1 resolved almost completely and there was modest improvement in case 2. Tolerance to repeated courses of rituximab suggests that maintenance therapy may be possible and should be explored in patients who respond to rituximab therapy, a strategy that has been successfully used in patients with follicular lymphoma. Figure 2 This patient had extensive chronic sclerodermoid GVHD. He was previously treated at 14 months post transplant for nephrotic syndrome and remained stable for several years. He had massive proteinuria at 95 months post transplant and was then started on secondand third-course rituximab (3 months apart).
